PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?

Table 4

Association between the expression of PD-L1 on neoplastic cells and inflammatory infiltrate, stromal TILs, Ki67, clinical T, clinical N, and pCR in the multivariate analysis.

	(%)	pCR
		(%)	value	ORR (CI)
Stromal TILs
Low	32 (60%)	8 (25%)	0.5	1,61 (0,40–6,52)
High	22 (40%)	11 (50%)
PD-L1 on tumor cells
0%	35 (65%)	11 (31%)	0.038	1,13 (1,01–1,27)
1–25%	15 (28%)	4 (27%)
≥25%	4 (7%)	4 (100%)
PD-L1 on inflammatory cells
Negative	10 (18%)	3 (30%)	0.058	0,09 (0,01–1,08)
Positive	44 (82%)	15 (34%)
Ki-67
<50%	14 (26%)	4 (28%)	0.054	1,05 (1–1,09)
≥50%	40 (74%)	15 (37%)
Clinical T
T1	7 (13%)	3 (43%)	0.8	0,8 (0,08–8,09)
T2–T4	47 (87%)	16 (34%)
Clinical N
Negative	30 (55%)	13 (43%)	0.27	0,47 (0,12–1,82)
Positive	24 (45%)	6 (25%)